BioWorld

Feb. 23, 2005

View Archived Issues

With Positive INKP-102 Results, InKine Prepares For NDA Filing

InKine Pharmaceutical Co. Inc. said its pre-colonoscopy bowel-cleansing drug, INKP-102, met or exceeded endpoints in a Phase III trial compared to the company's marketed purgative product, Visicol. (BioWorld Today) Read More

Codexis Acquiring German Biocatalysts Company Julich

Read More

Speedel Brings In CHF47.8M To Advance Pipeline Projects

Read More

Phase III Trial Under Way For Icagen's Sickle Cell Product

Read More

Other News To Note

Read More